Daily Briefing – May 31: ASCO weekend puts oncology catalysts back in focus, Dell and NetApp keep AI infrastructure leadership alive, Replimune stays a high-volatility FDA story, oil relief remains conditional, and the record tape enters a selective follow-through test

The latest weekend update shifts the tape from a pure earnings reaction into a broader follow-through test. Friday’s market already rewarded the clearest AI-infrastructure signals: Dell reset the server conversation with record revenue, a sharply higher full-year outlook and massive AI-server demand, while NetApp confirmed that storage and enterprise data infrastructure are becoming part of the same AI buildout. But the new layer is ASCO 2026. Oncology news is now moving from preview mode into data mode, with Exelixis strengthening CABOMETYX in neuroendocrine tumors, Corcept reinforcing the Lifyorli launch story in platinum-resistant ovarian cancer, BioNTech and Bristol Myers adding fresh PD-L1 x VEGF lung-cancer data, and Pfizer keeping the prostate-cancer PARP-combination debate active. Replimune remains the most volatile biotech catalyst after saying it will resubmit the RP1 BLA in the coming days, with the FDA indicating the resubmission will be treated as an urgent matter. Macro is supportive but not clean: oil eased on hopes for a U.S.-Iran ceasefire extension and possible Hormuz relief, while Reuters also reported new U.S. sanctions targeting Iran-linked military oil sales. The bottom line: AI infrastructure is still the cleanest leadership pocket, ASCO is adding biotech-specific catalysts, and the broader tape remains constructive but highly selective.

Main single-stock stories

DELL— Dell remains the lead AI-infrastructure signal after record fiscal Q1 revenue of $43.8 billion, a large EPS beat, strong AI-server orders and a raised FY27 revenue outlook around a $167 billion midpointAI Servers
DELL / NVDA— The core read-through is that Nvidia-powered AI server demand is still visible in real orders, backlog and guidance, not only in long-term AI commentaryAI Compute
NTAP— NetApp keeps storage inside the AI trade after strong fiscal Q4 results, with investors focusing on enterprise data infrastructure, cloud storage and AI workload supportAI Storage
SMCI / HPE— Super Micro and Hewlett Packard Enterprise remain direct read-through names from Dell, especially for rack-scale AI systems, enterprise deployment and server-margin qualityServer Basket
VRT / GEV / ETN— Data-center power, cooling and electrical-infrastructure names stay in focus because AI server and storage growth increases pressure on physical capacityPower / Cooling
AVGO / MRVL / MU— Networking, custom silicon and memory remain tied to the AI buildout as Dell’s AI-server order strength supports the broader data-center supply chainAI Supply Chain
EXEL— Exelixis becomes an ASCO watch name after CABINET subgroup data showed CABOMETYX PFS benefit in both non-functional NET and functional NET, supporting the 2025 NET approval storyASCO / NET
CORT— Corcept presented ASCO data showing Lifyorli survival benefit across ROSELLA subgroups, including recent taxane exposure, strengthening the oncology launch narrativeASCO / Oncology
BNTX / BMY— BioNTech and Bristol Myers are in focus after ASCO data for pumitamig/BNT327 plus chemotherapy in first-line NSCLC showed encouraging anti-tumor activity across histologies and PD-L1 levelsASCO / Lung
PFE— Pfizer’s TALAPRO-3 keeps attention on Talzenna plus Xtandi in HRR-mutated metastatic castration-sensitive prostate cancer, adding another large-cap oncology read-through from ASCOASCO / GU
REPL— Replimune remains the most explosive FDA catalyst after announcing a planned RP1 BLA resubmission, with the FDA indicating it will treat the resubmission as an urgent matterFDA / Biotech
BMY / REPL— RP1 is being pursued with Bristol Myers’ Opdivo in advanced melanoma, keeping the setup highly dependent on FDA review posture and resubmission timingOncology
OKTA— Okta remains the positive cybersecurity read after better execution, raised expectations and a more concrete identity-security angle around AI agentsIdentity Security
S— SentinelOne remains the cautious cybersecurity read: revenue and ARR growth are not enough while investors focus on guidance quality, restructuring and the 8% workforce reduction planCybersecurity
COST / GAP / AEO— Consumer remains split: Costco supports the value/membership model, while Gap and American Eagle keep the apparel and discretionary-demand tape fragileConsumer

Macro & tape pressure

Record tape— U.S. indexes ended Friday higher, with the market entering the weekend near records and the follow-through test now shifting to AI breadth, ASCO catalysts and oil headlinesMarket
AI vs breadth— The headline tape is constructive, but leadership is still concentrated in companies with visible AI revenue, orders, backlog, storage demand or data-center exposureBreadth
ASCO rotation— Oncology names can start moving on real data rather than previews, especially where ASCO updates connect directly to approvals, launch execution or near-term FDA eventsBiotech
Oil relief— Crude eased on hopes for a U.S.-Iran ceasefire extension and possible Hormuz relief, but the situation remains unresolved and headline-sensitiveOil / Geo
Sanctions offset— Fresh U.S. sanctions on Iran-linked military oil sales show the geopolitical risk premium has not fully disappeared even as traders price in a possible cooling pathGeo Risk
Yields matter— Lower oil helps inflation psychology, but growth-stock leadership still needs contained Treasury yields; if yields rise, speculative growth and small caps become more vulnerableRates
Fund flows— Recent inflow data support the idea that technology strength is pulling capital back into U.S. equity funds, but the leadership remains heavily AI-centeredFlows
Consumer split— Costco’s resilience contrasts with weakness in apparel, confirming that consumer strength is segmented rather than broad and uniformConsumer
Software split— Okta and SentinelOne show that AI language helps only when paired with clean execution, better guidance, cash flow or credible enterprise demandSoftware
Weekend risk— With stocks near records and oil still geopolitical, a calm weekend supports continuation; a Hormuz or ceasefire reversal can hit risk appetite quicklyTape

Themes & rotation

AI infrastructure remains the cleanest trade— Dell and NetApp show the market is still rewarding AI when demand appears in revenue, orders, backlog, storage, margins and guidanceAI Infra
Physical AI beats generic AI— Servers, storage, networking, memory, power and cooling are getting more credit than vague software AI narratives because investors can connect them directly to capexHardware
Storage joins the AI stack— NetApp’s strength matters because the AI buildout is not only GPUs; data access, hybrid cloud and enterprise workload management are part of the same tradeStorage
ASCO can create single-name dispersion— EXEL, CORT, BNTX/BMY and PFE show that oncology updates can move very different types of companies: profitable platform, launch story, bispecific pipeline and large-cap pharmaASCO
FDA-path volatility is back— Replimune shows how quickly a regulatory path can reprice a biotech, but the setup remains binary until FDA timing and review outcome become clearerFDA
Oncology launch support matters— CORT and EXEL are not just trial-data stories; their updates also support launch messaging and physician confidence around already approved productsLaunch
Identity security has the cleaner AI angle— Okta’s AI-agent identity narrative is concrete because autonomous agents create real access, governance and security problemsAI Agents
Oil relief supports multiples— Lower crude helps growth-stock psychology, but the Hormuz situation remains too conditional to treat as solvedOil Relief
Retail remains selective— Costco supports the value/membership model, while Gap and American Eagle warn that apparel demand and discretionary categories remain fragileRetail

Tickers to monitor

DELL / SMCI / HPE— AI server basket: Dell is the lead signal, while Super Micro and HPE are direct server and rack-scale read-through names to monitor nextAI Servers
NTAP / WDC / STX— Storage watch: NetApp can pull attention toward enterprise storage, cloud data infrastructure and the storage side of AI workloadsStorage
NVDA / AVGO / MRVL / AMD— AI semiconductor basket: Dell’s AI-server demand reinforces compute, networking and custom-silicon exposureAI Semis
MU / WDC / STX— Memory and storage watch: stronger AI server demand supports HBM, DRAM, SSD and enterprise storage themes if capex durability holdsMemory
VRT / GEV / ETN— Power and data-center infrastructure basket: watch whether AI-server strength pulls more money into cooling, electrical systems and grid-capacity namesPower
EXEL / CORT— ASCO launch-support basket: Exelixis and Corcept both have updates that reinforce already approved oncology products rather than create brand-new approvalsASCO
BNTX / BMY / SMMT— PD-L1 x VEGF watch: BioNTech/Bristol Myers’ pumitamig data keep attention on a class that investors also compare with Summit/Akeso’s ivonescimab storyBispecifics
REPL / BMY— FDA catalyst watch: Replimune’s RP1 resubmission path can remain volatile as traders wait for formal timing and the next agency actionFDA Watch
OKTA / S / ZS / CRWD / PANW— Cybersecurity watch: Okta is the positive identity-security signal, SentinelOne is the restructuring/guidance test, and the group needs clean executionSecurity
COST / WMT / TGT— Value and household-resilience basket: Costco remains the clean membership/value read, while Walmart and Target help confirm whether consumer strength is broad or narrowConsumer
GAP / AEO / ANF / URBN— Apparel and discretionary watch: Gap and American Eagle keep pressure on the group, especially if investors decide fashion demand is weakening faster than broader retailApparel
OXY / XOM / CVX / USO / XLE— Energy remains tied to the U.S.-Iran/Hormuz tape. A real reopening path pressures crude; renewed conflict headlines can restore risk premium fastEnergy
SPY / QQQ / SOXX / IWM / XBI— Macro proxies: QQQ and SOXX show AI leadership, IWM and XBI test breadth, and SPY shows whether the record tape can absorb geopolitical riskMacro Watch

Tape watch

First test: DELL digestion— Dell needs to hold its post-earnings move after the first excitement wave. If it does, AI infrastructure remains the cleanest leadership pocketDELL
Second test: NTAP follow-through— NetApp is important because it broadens the AI trade from chips and servers into enterprise data infrastructure and storageNTAP
Third test: ASCO movers— Watch whether EXEL, CORT, BNTX/BMY, PFE and REPL create follow-through or fade once the first weekend headlines are digestedASCO
Fourth test: REPL volatility— Replimune can remain highly active because FDA-path news reprices fast, but the setup remains binary until the agency’s next decision is clearerFDA
Fifth test: oil headlines— The market likes Hormuz relief hopes, but any reversal in ceasefire, shipping, insurance or military headlines can quickly pressure risk assetsOil
Sixth test: yields— If Treasury yields stay calm, AI leadership can broaden. If yields rise, leadership may narrow back to the highest-quality mega-cap and infrastructure winnersRates
Seventh test: OKTA vs S— Cybersecurity is split: Okta can support identity-security sentiment, while SentinelOne keeps pressure on names where guidance or execution look weakerSecurity
Eighth test: retail split— Costco, Gap and American Eagle show whether investors buy consumer resilience broadly or hide only in the strongest value-oriented retail modelsRetail
Ninth test: breadth— IWM and XBI are important breadth checks. If they lag while QQQ/SOXX lead, the tape is constructive but still narrow and rates-sensitiveBreadth
Main read— May 31 is an AI-infrastructure plus ASCO-catalyst tape, supported by oil relief but still selective, headline-sensitive and dependent on clean follow-throughBottom Line

Free Course

Run-Up Biotech Masterclass

Learn how to read biotech catalysts, trial results and FDA decisions with a practical framework.

Open

Educational only.

Tracking Tool

Biotech Catalyst Calendar

Track FDA events, clinical readouts and biotech catalysts with a practical event-driven tool.

Open Archive

Browse the Blog & Archive

Explore articles, biotech deep dives, market notes, reports and archived sector content.

Open Reality Check

Biotech Trading Without the Fairy Tales

A grounded piece on risk, catalysts, dilution, volatility and biotech trading reality.

Open 2026 Watchlist

The New Era – Space, Defense & AI

A thematic watchlist built around military spending, strategic technology and AI-linked trends.

Open Briefing

SPACE AI DEFENCE

A thematic briefing at the intersection of defense, space infrastructure and AI.

Open Top List

Top 10 Defense-Tech Stocks to Watch

A focused list built around defense technology, drones and strategic systems.

Open Top List

Top 5 U.S. Airlines Watchlist

A practical watchlist for pricing power, fuel sensitivity, travel demand and macro tone.

Open Top List

Top 5 Cruise Lines Watchlist

A leisure-focused list centered on major cruise operators and pricing-driven sentiment.

Open

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and sector rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 to get 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with professional charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day and swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Authors: Merlintrader, Jane and Gemini

Author’s note

In every report I share what I see and how I personally interpret it, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants, which help me organize the data, re-check details and improve charts or visual elements. However, any interpretation, opinion and final judgment remain entirely mine, as a trader and not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is a complex job, so inaccuracies may occur. If you notice something that seems off, feel free to tell me and I will correct it. Please do not treat this report as professional investment advice, but as one more source of information to compare with your own research and with the opinion of qualified professionals.

AI usage disclosure

This report has been prepared using a human + AI workflow. Drafting, editing and data organization are supported by generative AI tools, such as large language models provided by third parties, based on prompts and instructions defined by the author. All sources used are public, and the final selection of data, checks, opinions and conclusions remains with the author, who takes full responsibility for the content.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs, so the content can remain independent and freely accessible.

Biotech Catalyst Calendar

For a broader and continuously updated view of upcoming biotech catalysts — PDUFA dates, major clinical readouts, regulatory events and key conferences — you can visit the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar